in

Biopharmaceutical company: Abeona Therapeutics (ABEO) (1989)

Abeona Therapeutics Inc. (NYSE: ABEO) was founded in 1989, formerly PlasmaTech Biopharmaceuticals, Inc., changed to its current name in June 2015, headquartered in Dallas, Texas, with 88 full-time employees. It is a clinical-stage biopharmaceutical the company.

Abeona Therapeutics ABEO Logo

Abeona Therapeutics (ABEO):

Abeona Therapeutics is a biopharmaceutical company that focuses on the development and delivery of gene therapy and plasma-based products to treat serious and life-threatening rare diseases. Abeona Therapeutics’ product candidates mainly include:

  • AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH): Adeno-associated virus (AAV)-based gene therapy for the treatment of San Filippo syndrome (MPS IIIB and IIIA);
  • ABO-201 (scAAV9 CLN3): Gene therapy to treat adolescent Batten disease (JBD);
  • ABO-301 (AAV LK19 FANCC): CRISPR/Cas9-based gene therapy to treat Fanconi anemia (FA) and other rare blood diseases;

In addition, Abeona Therapeutics is developing rare plasma protein therapies, including SDF AlphaT (α-1 protease inhibitor).

In addition, Abeona Therapeutics is also involved in the sale of MuGard and ProctiGard, the former is a treatment for oral wounds, stomatitis, oral ulcers and traumatic ulcers, and the latter is used for the treatment of rectal mucositis and proctitis.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all Intels

Automobile transportation: Swift Transportation (SWFT), an American transit transportation company-delisting (1966)

Atlas Air Worldwide: Atlas Air Worldwide Holdings (AAWW) (1992)